2026.11.02
[Biopioneers Panel] Bispecifics, Trispecifics and Beyond: Shaping the Next Wave of Global Drug Innovation
Panel OverviewAs antibody-based therapies continue to evolve, multispecific therapeutics are moving beyond early scientific concepts toward clinical development and commercialization. Recent advances, including head-to-head clinical data for PD-1/VEGF bispecifics against established standards of care, as well as progress in bispecific ADCs, TL1A-targeting bispecifics, and trispecific T-cell engagers, highlight the growing potential of these therapies across different disease areas. Yet significant challenges remain. With growing competition and increasingly crowded pipelines, the industry faces critical questions around clinical validation, meaningful differentiation, molecular design, CMC development, and scalable manufacturing. Meanwhile, rising global interest in innovative biotech assets is opening new opportunities for licensing and cross-border collaboration, alongside new challenges and risks. To explore these emerging opportunities and challenges, China BioPioneers · International Edition returns for Episode 3. Co-hosted by @AsymBio, ISWTC (InScienceWeTrust Community), Healthcare Executive, and Weijieyao, bringing together biotech executives and industry experts to explore the evolving landscape of multispecific therapeutics and the next wave of global drug innovation. In this panel, we will examine what has truly been validated, where the next generation can differentiate, how CMC strategies can support successful development, and what opportunities lie ahead for global collaboration. What We Will Cover:1. Why Bispecifics and Trispecifics? --- The unique value of multispecific design beyond monoclonal antibodies2. Design Decisions That Make or Break a Multispecific3. CMC as a Strategy --- How Manufacturing Becomes a Competitive Moat4. Why Are Western Pharma, Biotech, and Investors So Drawn to Chinese Multispecific Assets?5. Beyond Oncology and Immunology, Where Will Multispecifics Deliver Next? Click to Register